Detailed Information on Publication Record
2018
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ et. al.Basic information
Original name
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
Authors
POPRACH, Alexandr (203 Czech Republic, guarantor, belonging to the institution), Ondrej FIALA (203 Czech Republic), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Katarína PETRÁKOVÁ (203 Czech Republic, belonging to the institution), Milada ZEMANOVA (203 Czech Republic), Katerina KOPECKOVA (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Hana STUDENTOVA (203 Czech Republic), Jindrich KOPECKY (203 Czech Republic), Igor KISS (203 Czech Republic, belonging to the institution), Jindrich FINEK (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and Tomas BUCHLER (203 Czech Republic)
Edition
Anticancer Research, Athens, The International Institute of Anticancer Research, 2018, 0250-7005
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.935
RIV identification code
RIV/00216224:14110/18:00102719
Organization unit
Faculty of Medicine
UT WoS
000419130100060
Keywords in English
Renal cell carcinoma; pazopanib; response; survival; cancer registry
Tags
International impact, Reviewed
Změněno: 26/4/2021 13:46, Mgr. Tereza Miškechová
Abstract
V originále
Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Links
ED1.1.00/02.0068, research and development project |
| |
NT13547, research and development project |
| |
NV15-34678A, research and development project |
| |
90004, large research infrastructures |
|